FDA Removes "Black Box" Warnings on Menopause Hormone Therapies

FDA's Decision on Hormone Therapy Warnings

• FDA is removing "black box" safety warnings from many hormone therapy drugs used for menopause and perimenopause symptoms.
• These warnings previously indicated increased risks of breast cancer, dementia, heart attack, and strokes.
• The decision impacts medications containing estrogen and progesterone in various forms like pills and creams.

Re-evaluation of Safety Studies

• FDA Commissioner Dr. Marty McCary stated that the original study supporting the warnings lacked statistical significance and subsequent trials did not confirm increased breast cancer mortality.
• He highlighted potential long-term health benefits of hormone therapy, including reductions in cognitive decline, heart attacks, bone fractures, cancer, and diabetes.
• Dr. McCary suggested that the original study was flawed and contributed to a